Plenty of places in the world are messed up, but Europe has been near the top of the list lately. If all the horrible scenarios play out, this will be the year the euro collapses, the European Union fractures, and some economically advanced countries could go bust.
Yet while the world financial system holds its breath, a few American venture capitalists have suddenly started looking at Europe like it’s the new land of biotech opportunity. Check the headlines from the past few weeks:
—Domain Associates, a top life sciences venture firm in Princeton, NJ and San Diego, struck a deal with Rusnano, a Moscow-based nanotechnology firm owned by the government of the Russian Federation, to invest as much as $760 million in biotech companies in both the U.S. and Russia. Rusnano and Domain said they will work together to transfer technology into Russia, and build up biotech development and manufacturing capabilities.
To read the full, original article click on this link: Biotech’s New Frontier: Europe? | Xconomy
